BRPI0618455A2 - composição de geléia - Google Patents

composição de geléia Download PDF

Info

Publication number
BRPI0618455A2
BRPI0618455A2 BRPI0618455-3A BRPI0618455A BRPI0618455A2 BR PI0618455 A2 BRPI0618455 A2 BR PI0618455A2 BR PI0618455 A BRPI0618455 A BR PI0618455A BR PI0618455 A2 BRPI0618455 A2 BR PI0618455A2
Authority
BR
Brazil
Prior art keywords
composition
active ingredient
jelly
taking
storage stability
Prior art date
Application number
BRPI0618455-3A
Other languages
English (en)
Inventor
Hiroki Ueshima
Shigeharu Suzuki
Naomi Yokomizo
Atsushi Sato
Hirosato Fuji
Shigeru Kimura
Original Assignee
Mochida Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mochida Pharm Co Ltd filed Critical Mochida Pharm Co Ltd
Publication of BRPI0618455A2 publication Critical patent/BRPI0618455A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

COMPOSIçãO DE GELéIA. A presente invenção refere-se a uma composição tendo pelo menos um efeito entre os seguintes efeitos; uma pluralidade de ingredientes medicinais que podem ser tomados como uma preparação e a conveniência para os pacientes é excelente; a concordância com fármaco é excelente; a quantidade de composição de geléia a ser tomada de uma vez é pequena; a liberação de um ingrediente ativo no trato digestivo é excelente; a absorção de um ingrediente ativo para o corpo é excelente; a estabilidade de armazenagem de um ingrediente ativo é excelente; a dispersabilidade de um ingre- diente ativo em uma composição é excelente; a estabilidade de armazenagem da composição é excelente; a sinérese da composição é menor, ela tem uma resistência de geléia apropriada para um grau que não se desintegra durante o transporte e antes de tomar, e facilmente desintegra-se depois de tomar; a capacidade de manipular durante a preparação da composição é excelente; a portabilidade da composição é excelente; a sensação de tomar a composição é excelente; tem um efeito na redução de efeitos colaterais; e similares. A composição de geléia contém um ácido graxo insaturado polivalente, um segundo ingrediente medicinal, um agente de emulsificação e um agente de gelificação.
BRPI0618455-3A 2005-11-11 2006-11-10 composição de geléia BRPI0618455A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2005327341 2005-11-11
JP2006040799 2006-02-17
PCT/JP2006/322483 WO2007055327A1 (ja) 2005-11-11 2006-11-10 ゼリー組成物

Publications (1)

Publication Number Publication Date
BRPI0618455A2 true BRPI0618455A2 (pt) 2011-08-30

Family

ID=38023321

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0618455-3A BRPI0618455A2 (pt) 2005-11-11 2006-11-10 composição de geléia

Country Status (8)

Country Link
US (1) US8962682B2 (pt)
EP (1) EP1946755B1 (pt)
JP (1) JP5113527B2 (pt)
KR (1) KR101292573B1 (pt)
CN (1) CN101309679B (pt)
BR (1) BRPI0618455A2 (pt)
CA (1) CA2628305C (pt)
WO (1) WO2007055327A1 (pt)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5340823B2 (ja) * 2008-06-24 2013-11-13 ナガセ医薬品株式会社 医療用潤滑剤
EP4137128A1 (en) 2008-09-02 2023-02-22 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and a statin, and methods of using same
GB0818473D0 (en) 2008-10-08 2008-11-12 Probio Nutraceuticals As Composition
GB0818472D0 (en) * 2008-10-08 2008-11-12 Probio Nutraceuticals As Composition
ES2768091T3 (es) 2009-02-10 2020-06-19 Amarin Pharmaceuticals Ie Ltd Uso del éster etílico del ácido eicosapentaenoico para tratar la hipertrigliceridemia
NZ720946A (en) 2009-04-29 2017-09-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
MX350088B (es) 2009-04-29 2017-08-25 Amarin Pharma Inc Composicion farmaceutica estable y metodos de uso de la misma.
CN108096209A (zh) 2009-06-15 2018-06-01 阿马里纳制药公司 在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl-c水平的组合物和方法
US20110071176A1 (en) 2009-09-23 2011-03-24 Amarin Pharma, Inc. Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
JP5660797B2 (ja) * 2010-03-31 2015-01-28 テルモ株式会社 水分補給ゼリー
NZ712068A (en) 2010-11-29 2017-03-31 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US20130131170A1 (en) 2011-11-07 2013-05-23 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
ES2891473T3 (es) 2012-01-06 2022-01-28 Amarin Pharmaceuticals Ie Ltd Composiciones y métodos para reducir los niveles de alta sensibilidad (hs-CRP) en un sujeto
WO2013142482A1 (en) * 2012-03-20 2013-09-26 Particle Dynamics International, Llc Gelling agent-based dosage form
US9480651B2 (en) 2012-03-30 2016-11-01 Sancilio & Company, Inc. Omega-3 fatty acid ester compositions unitary pharmaceutical dosage forms
US10898458B2 (en) 2012-03-30 2021-01-26 Micelle Biopharma, Inc. Self-micellizing fatty acids and fatty acid ester compositions and their use in the treatment of disease states
US20160228397A1 (en) 2012-03-30 2016-08-11 Sancilio & Company, Inc. Omega-3 fatty acid ester compositions
EP2830602B1 (en) 2012-03-30 2020-10-21 Micelle BioPharma, Inc. Omega-3 fatty acid ester compositions
CA3067012C (en) 2012-06-29 2021-10-05 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
BR112014032699A2 (pt) * 2012-06-29 2017-06-27 Amarin Pharmaceuticals Ie Ltd métodos de tratamento de síndrome metabólica pediátrica
WO2014074552A2 (en) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
JP6267862B2 (ja) * 2012-11-26 2018-01-24 Ｅａファーマ株式会社 ゼリー化組成物
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
JP6163084B2 (ja) * 2013-11-11 2017-07-12 キリン株式会社 認知症の予防、治療及び／又は認知機能を改善する組成物、及びこれを用いた医薬、食品
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
US10172818B2 (en) 2014-06-16 2019-01-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
CN104911027A (zh) * 2015-06-19 2015-09-16 江苏复生生物科技有限公司 用天然抗氧剂提高食用植物油或鱼油抗氧化性能的方法
KR20170069320A (ko) * 2015-12-10 2017-06-21 롯데정밀화학 주식회사 히드록시프로필메틸 셀룰로오스를 함유하는 반고체 식품
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
WO2018213663A1 (en) 2017-05-19 2018-11-22 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
JP6670287B2 (ja) * 2017-12-25 2020-03-18 Ｅａファーマ株式会社 ゼリー化組成物
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
MA51766A (fr) 2018-09-24 2020-12-16 Amarin Pharmaceuticals Ie Ltd Procédés de réduction du risque d'événements cardiovasculaires chez un sujet
KR102390067B1 (ko) * 2019-04-01 2022-04-28 코스맥스엔비티 주식회사 이미 및 이취를 억제하기 위한 다가불포화지방산을 함유하는 오일을 포함하는 유화오일 조성물, 이를 포함하는 식품 및 이들의 제조방법
US11547664B2 (en) * 2019-06-07 2023-01-10 The Regents Of The University Of California Compositions and methods for treating eosinophilic disorders
BR112022009189A2 (pt) 2019-11-12 2022-07-26 Amarin Pharmaceuticals Ie Ltd Métodos para reduzir o risco de eventos cardiovasculares em um sujeito com fibrilação atrial e/ou palpitação atrial
KR20220096718A (ko) 2020-12-31 2022-07-07 주식회사 제뉴원사이언스 도네페질 또는 이의 약학적으로 허용되는 염을 포함하는 도네페질 젤리 제제
US11986452B2 (en) 2021-04-21 2024-05-21 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure
US20240350402A1 (en) * 2021-08-31 2024-10-24 The Cleveland Clinic Foundation Topical drug treatment to prevent or reduce corneal scarring
WO2026023007A1 (ja) * 2024-07-25 2026-01-29 株式会社ニッスイ 粒状ゲル食品

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2687231B2 (ja) * 1989-01-12 1997-12-08 月島食品工業株式会社 ゲル化食品の製造法
JP3004442B2 (ja) * 1992-01-27 2000-01-31 サンスター株式会社 口腔用組成物
JP3531994B2 (ja) * 1995-03-13 2004-05-31 旭電化工業株式会社 層状ゼリー及びその製造方法
WO1997025024A1 (en) * 1996-01-12 1997-07-17 Ohta Pharmaceutical Co., Ltd. Jellied medicinal composition for oral administration
JP2974204B2 (ja) 1996-02-20 1999-11-10 日本合成化学工業株式会社 γ−リノレン酸含有ゼリー状キャンディー及びその製造法
JPH1156245A (ja) * 1997-08-22 1999-03-02 Nippon Synthetic Chem Ind Co Ltd:The 油脂含有ゼリー状キャンディー及びその製造法
JPH1156315A (ja) * 1997-08-22 1999-03-02 Nippon Synthetic Chem Ind Co Ltd:The γ−リノレン酸含有飲料
ID25929A (id) * 1998-01-08 2000-11-09 Otsuka Food Co Ltd Produk makanan gelatin dan proses penyediaannya
JP2000128805A (ja) 1998-10-27 2000-05-09 Nippon Suisan Kaisha Ltd 多価不飽和脂肪酸および高分子ゲルからなる経粘膜吸収促進剤及びそれを含有する薬剤
GB9916536D0 (en) * 1999-07-14 1999-09-15 Scarista Limited Nutritional or pharmaceutical compositions
JP5241978B2 (ja) 1999-10-13 2013-07-17 帝國製薬株式会社 漢方ゼリー医薬組成物
JP3776649B2 (ja) * 1999-10-21 2006-05-17 森永乳業株式会社 機能性素材含有微生物セルロースゲル及びその製造方法
JP2002153218A (ja) * 2000-11-24 2002-05-28 Beruricchi:Kk 食物繊維及びドコサヘキサエン酸を多く含むゼリー状食品
WO2002043659A2 (en) * 2000-11-29 2002-06-06 Smithkline Beecham Corporation Composition containing statins and calcium for improved cardiovascular health
ITMI20012366A1 (it) 2001-11-09 2003-05-09 Farmatron Ltd Sistemi terapeutici stabilizzati a rilascio immediato e/o modificato per la somministrazione orale di principi attivi e/o eccipienti e/o ali
US20040018248A1 (en) * 2001-11-29 2004-01-29 Adrianne Bendich Composition containing statins and calcium for improved cardiovascular health
WO2003103640A1 (en) * 2002-06-10 2003-12-18 Elan Pharma International, Ltd Nanoparticulate formulations comprising hmg coa reductase inhibitor derivatives (“statins”), novel combinations thereof as well as manufacturing of these pharmaceutical compositions
JP3941599B2 (ja) 2002-06-11 2007-07-04 日本油脂株式会社 中鎖脂肪含有ゲル状食品
JP4586336B2 (ja) * 2003-05-13 2010-11-24 ゼリア新薬工業株式会社 脂溶性物質含有水性液剤
JP4304029B2 (ja) * 2003-09-09 2009-07-29 テイコクメディックス株式会社 シロスタゾールゼリー状医薬組成物
CA2577345C (en) * 2004-08-18 2013-02-19 Hiroki Ueshima Jelly composition

Also Published As

Publication number Publication date
EP1946755A1 (en) 2008-07-23
JPWO2007055327A1 (ja) 2009-04-30
WO2007055327A1 (ja) 2007-05-18
EP1946755B1 (en) 2017-03-15
CA2628305A1 (en) 2007-05-18
CN101309679A (zh) 2008-11-19
CN101309679B (zh) 2013-07-24
EP1946755A4 (en) 2012-12-26
JP5113527B2 (ja) 2013-01-09
US8962682B2 (en) 2015-02-24
KR101292573B1 (ko) 2013-08-12
US20090111777A1 (en) 2009-04-30
KR20080070852A (ko) 2008-07-31
CA2628305C (en) 2014-05-06

Similar Documents

Publication Publication Date Title
ES2640745T3 (es) Composiciones lubricantes que producen calor y no irritantes
ES2291377T3 (es) Pelicula de espuma de celdas cerradas bioadhesiva de liberacion sostenida.
CN101309679A (zh) 胶冻组合物
Bakshi et al. A placebo‐controlled comparative evaluation of diclofenac dispersible versus ibuprofen in postoperative pain after third molar surgery
CN101588797A (zh) 带有最小化副作用包括减轻肝毒性的对乙酰氨基酚组合物
PE20030323A1 (es) Composicion farmaceutica
CA2577350A1 (en) Vaginal cream compositions, kits thereof and methods of using thereof
JP2011088930A (ja) 二酸化炭素経皮・経粘膜吸収用組成物
JP5403935B2 (ja) 経口用の慢性疼痛予防または治療剤
ES2266288T3 (es) Pulverizador nasal tixotropico.
CN104940163A (zh) 一种胶囊壳体
JP5643872B2 (ja) 二酸化炭素経皮・経粘膜吸収用組成物
Al-Na'mah et al. Dexamucobase: a novel treatment for oral aphthous ulceration.
Swami et al. Accidental intraoral injection of formalin during extraction: case report
JP5164438B2 (ja) 二酸化炭素経皮・経粘膜吸収用組成物
JP5699184B2 (ja) 二酸化炭素経皮・経粘膜吸収用組成物
JP5279343B2 (ja) 坐薬製剤組成物
Hersh et al. A study of benzocaine gel dosing for toothache
EP1101491A2 (en) Soft gelatine capsules containing olive oil
PT705085E (pt) Sistema de transporte transdermico de moleculas
ES2441917B1 (es) Composición farmacéutica para uso en inflamación y dolor
ES2938358T3 (es) Formulación farmacéutica para el tratamiento de modificaciones inflamatorias del recto
Vijayshankar et al. A prospective study of prathisaraneeya apamarga kshara in comparison with prathisaraneeya palasha kshara in patients with charmakeela (warts) and kadara (corns)
CN205433979U (zh) 冷疗牙胶
Suwannarurk The effectiveness of sublingual or oral administration of misoprostol for cervical ripening before manual vacuum aspiration in first trimester termination of pregnancy: randomized controlled trial

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 13A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2539 DE 03-09-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.